Dear Sirs,

We read with interest Morassi et al. case series, \[[@CR2]\] where they and others \[[@CR1], [@CR3]\] reported stroke as a complication of severe COVID-19 infection. The effect of COVID-19 on acute stroke patients (ischaemic and haemorrhagic) who may catch the disease concomitantly with stroke or after stroke but not as a cause of severe COVID-19 disease is not known. Therefore, we detail the demographic, clinical, radiological, laboratory results, treatment and outcomes of 22 consecutive COVID-19-positive (confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR)) stroke patients diagnosed during the lockdown period 23rd March to 1st May 2020 inclusive at a tertiary London neuroscience centre. The mean age is 70.3 ± 2.2 years (range 49--83 years old, 14 (64%) males and 8 (36%) females). We classified these patients into (i) hospital acquired COVID-19; those who developed COVID-19 in the hospital while being treated for stroke, (ii) community acquired COVID-19; patients who had COVID-19 symptoms in the community shortly before attending the hospital with stroke and (iii) stroke as a direct complication of COVID-19; patients who were treated in intensive care with obvious prothrombotic state.

Table [1](#Tab1){ref-type="table"} cases 1--5 are hospital acquired COVID-19, this category of patients has not been described before. These were the patients being treated for stroke in mid-March 2020, when wearing personal protective equipment (PPE) was not recommended for staff looking after non-COVID-19 patients. In addition, relative visiting rules were not restricted. Cases 2--5 had high poor functional status before hospital admission and high frailty score on admission. They presented with mild fever at the time of testing and normal chest X-ray. They received oxygen therapy by nasal canulae for their COVID-19 and did not require or proceed for intensive care input. Cases two and three were discharged home at similar level of function as before and the others deceased. It is interesting to note the two discharged patients had minimum elevation of high-sensitivity C-reactive protein (CRP). None of these patients had worsening of stroke symptoms. Table 1Demographic, clinical, radiological, laboratory findings, management and outcome of stroke patient who acquired COVID-19 at the hospitalCase 1Case 2Case 3Case 4Case 5Age/sex75/M67/F83/F74/M81/FEthnicityWhiteBlackWhiteWhiteWhitePast medical historyNonePrevious stroke, HTN, HL, T2DMAF on warfarin, HTN, IHD, CCFT2DM, IHD, CCF, AF, Non-Hodgkin's lymphomaAsthma, HTN, previous, stroke, AFMedicationsBisoprolol, Ramipril, Levetiracetam, Lansoprazole,Aspirin, atorvastatin, insulin, lansoprazole, levothyroxine, mirtazapine pregabalin, sitagliptin, quinineBisoprolol, Ramipril, bumetanide, simvastatin, warfarinAmiodarone, Amlodipine, atorvastatin, bisoprolol, tamsulosin, sitagliptin, bumetanide, candesartan, EdoxabanAmlodipine, Apixaban, Bisoprolol, Quetiapine, sertraline, salbutamolPre-stroke mRS14454Frailty score26686COVID symptoms and durationPatient was about to be discharged home from 8 weeks inpatient stroke rehab developed fever at the beginning of lockdownAfter 4 weeks inpatient stroke rehab developed fever at the beginning of lockdownAfter 10 days inpatient stroke rehab developed mild dry cough at the beginning of lockdownAfter 8 weeks inpatient rehab for stroke and infected prosthetic knee developed fever at the beginning of lockdownAfter 8 weeks inpatient stroke rehab developed fever at the beginning of lockdownSatO~2~/PaO~2~ (ABG) at the time of diagnosis98% RA96% RA96% RA96% RA96% RAChest X-ray/CT at presentationLung clearLung clearLung clearLeft lung mass and supradiaphragmatic lymph nodesLung clearCOVID treatmentNC O~2~, antibiotics, complicated with chest abscess, required chest drainNC O~2~NC O~2~NC O~2~, antibioticsNC O~2~Signs and symptoms of stroke2-day history of expressive dysphasia and disorientationDysarthria, left sided weaknessDysarthria with word finding difficultyVertigoLeft sided weakness and neglectVascular territory−Posterior circulationBilateral MCALeft PCARight MCAImaging for diagnosisCTMRIMRIMRICTImaging findingsLeft frontal haematoma with diffuse blood in convexity sulci bilaterally, cerebral Amyloid angiopathyLeft paramedian pontine infractBilateral embolic infarct in the right insula, right posterior temporal lobe, left frontal operculum and left occipital lobeLeft PCA embolic infarctRight parietal infarctChange in stroke after COVID-19No more bleed after COVID-19NoneNoneNoneNoneEvidence of PELarge saddle PENo CT-PANo CT-PANo PE on CT-PANo CT-PAWhite-cell count- × 10^9^/L25.9↑10.74.22.0↓10.4Lymphocytes count- × 10^9^/L0.8↓1.40.6↓0.7↓0.4↓Platelet count- × 10^9^/L214179156180235High-sensitivity C reactive protein-mg/L215↑↑27↑28↑354↑↑215↑↑Prothrombin time/INR1.4↑1.2↑1.2↑2.5↑1.4↑Activated partial thromboplastin time ratio1.011.000.961.010.87Fibrinogen-mg/dl5.3↑4.42.510.9↑4.0D-Dimer-ng/ml−−−−639↑Ferritin-µg/ml−−−899↑406↑Albumin-g/L27↓28↓31↓20↓24↓Clinical outcomePalliated after confirmed PE, deceased at 28 days after confirmed COVID-19 (mRS 6)Improved continue inpatient rehabilitation, then discharged home. (mRS 4)Improved, continued inpatient rehabilitation, then discharged home. (mRS 4)Deteriorated with ongoing suspected primary lung cancer, deceased 28 days after confirmed COVID-19 (mRS 6)3 weeks after Covid-19 positive, patient suffered a STEMI required PCI and coronary stenting. Cardiac arrest and deceased 7 days later (mRS 6)Case 6Case 7Case 8Case 9Case 10Case 11Case 12Case 13Case 14Case 15Case 16Case 17Age/sex75/M68/F68/F75/M77/M83/F50/M76/F49/M74/M83/M78/FEthnicityWhiteAsianWhiteWhiteWhiteBlackAsianBlackBlackWhiteWhiteAsianPast medical historyTerminal gastric cancer, IHD, AF, HTN, T2DM, CKDTraumatic brain injury PEG feed, Tracheostomy, T2DM, previous TIAHTN, CKDNoneHTN, T2DMDementia, T2 DMNoneT2DM, CKD4, HTN, IHDPrevious stroke, HTN, T2DM, HLAF on warfarin, schizophrenia, T2DM, HTN, IHD, CCF, hypothyroidismDementiaDementia, Pulmonary TB in 2012MedicationsApixaban, Amiodarone, Bisoprolol, Furosemide, Mirtazapine, Omeprazole,Amoxicillin, Citalopram, insulin, Levetiracetam, Metformin lansoprazole, RamiprilLMWH, levothyroxine, Mirtazapine, Ramipril, MetoclopramideNoneAmlodipine, Ramipril, Metformin, Gliclazide, Empagliflozin, AtorvastatinDonepezilNoneFurosemide, Tolterodine, Linagliptin, indapamide, pregabalin, Amlodipine, Aspirin, SimvastatinAtorvastatin, Amlodipine, clopidogrel, lansoprazole, metformin, gliclazide, perindopril, doxazosinWarfarin, citalopram, furosemide, levothyroxine, metformin, simvastatin, bisoprololDonepezilClopidogrel, atorvastatin, Doxazosin, Irbesartan, Etoricoxib, Metoprolol, LansoprazoleAdmitted fromHomeCare homeCare homeHomeHomeHomeHomeHomeHomeHomeCare homeCare homePre-stroke mRS354124031445Frailty score986237153677COVID symptoms and duration before stroke24 h fever cough2-day history of feverLow grade fever on 1 day after admissionLow grade fever dry cough 2 days after admission2-day history of fever, dizziness2-day history of fever3-day history of low-grade fever, cough1-day history of shortness of breath3-day history of feeling unwell2-week history of fever cough, confirmed COVID-19 positive 10 days before2-day history of fever and cough24 h prior to admission fever, cough, hypoxia on admissionSatO~2~/PaO~2~ (ABG) on admission98% on RA87% on 15L98% on RA98% on RA92% on RA92% on RA99% on RA93% on 15 L O~2~96% on RA92% on RA70% on 15 L O~2~89% on RAChest X-ray/CT at presentationGround-glass air space shadowing in the peripheryMild peripheral infiltrationIll-defined consolidation in the right mid zoneNormalBilateral multiple scattered air space opacitiesNormalNonspecific patchy bi-basal consolidationBilateral mid/lower zone patchy opacificationPatchy air space shadowing bilateral upper and mid zoneBilateral lower zone patchy opacificationDiffuse bilateral fine opacificationRight cardiophrenic angle opacity long standingCOVID treatmentNC O~2~, antibioticsNC O~2~NC O~2~NC O~2~Intubation, Remdesivir, LMWHNC O~2~NC O~2~NC O~2~,NoneNC O~2~NC O~2~ICU non-invasive ventilatorSigns and symptoms of strokeAphasia, right side and left leg weakness NIHSS 15Reduced GCS, worsening right side weaknessAcute right arm weakness, NIHSS 8Dizziness and unsteady gait, NIHSS 4TIAx2 last 7 days, acute left facial droop, right sided weaknessMild expressive aphasia, NIHSS 7Vertigo, unsteadiness, left facial numbnessAphasia, right side weaknessSlurred speech, right side weakness, NIHSS 7Slurred speech, left sided weakness, NIHSS 17Left sided weakness, with right eye deviationUnresponsive, left sided weakness, NIHSS 32Stroke onset to presentation (hr)15 hUnknown2 h, not thrombolysed due to recent hip surgery20 h12 h7 h6 h9 h8 h3 h not thrombolysed, on warfarin INR 3.61 h not thrombolysed as too unwell6 hVascular territoryLeft MCA, right ACALeft MCABilateral MCA−Posterior circulationLeft MCAPosterior circulationLeft MCALeft MCARight MCARight MCARight MCA, right M1 clotImaging for diagnosisCTMRIMRICTCTCTCTNot stable for CTCT/MRICTNot stable for CTCTImaging findingsLeft MCA, right ACA infarctLeft MCA embolic infarctBilateral border zone between MCA PCA, left more than rightIVH possibly secondary to AVMSVD, no large infarctSVD, no large infarctNo acute change on CT, right VA dissection on CTAn/aLeft uncus and internal capsule, and right corona radiata small infarctInitial CT right MCA early ischemia, 24 h CT confirmed complete right MCA infarctClinical right MCA strokeComplete right MCA infarctEvidence of PENo CTPANo CTPANo CTPANo CTPANo PE on CTPANo CTPANo CTPANo CTPANo CTPANo CTPANo CTPANo CTPAWhite-cell count- × 10^9^/L8.22.4↓10.5↑17.1↑15.2↑7.86.76.28.06.721.3↑8.3Lymphocytes count- × 10^9^/L0.7↓0.6↓0.6↓1.0↓0.3↓0.8↓0.8↓1.21.50.4↓1.41.1Platelet count- × 10^9^/L185224302281264223149259698↑155446342High-sensitivity C reactive protein-mg/L151↑134↑84↑61↑318↑↑59↑12↑136↑383↑418↑↑12↑Prothrombin time/INR1.2↑1.11.01.01.3↑1.11.01.21.03.6↑−1.0activated partial thromboplastin time ratio0.961.27↑0.940.891.23↑0.830.891.011.26↑1.34↑−1.00Fibrinogen-mg/dl5.9↑6.3↑4.9↑2.77.8↑5.2↑2.47.4↑8.4↑5.1↑−4.9↑D-Dimer-ng/ml−−909↑−3210↑−94−−−−−Ferritin-µg/ml−−603↑−3957↑−595↑−−−−628↑Albumin-g/L33↓24↓19↓3517↓32↓3630↓30↓24↓29↓25↓Clinical outcomeDeceased on day 3, after 40 min rapid deterioration in hypoxia and fast AF (mRS 6)Increased oxygen needs, Palliated deceased on day 4. (mRS 6)Improved continue inpatient rehabilitation (mRS 4)Improved, discharged home (mRS 1)Multiorgan failure, deceased on day 21 (mRS 6)Improved discharged home on day 3. (mRS 4)Improved, transfer to local hospital for stroke rehabilitation, then discharged home. (mRS 1)Palliated, deceased on day 2. (mRS 6)Improved, transferred to local hospital to rehabilitation then discharged home. (mRS 2)Palliated, deceased on day 5. (mRS 6)Palliated, deceased 12 h after admission. (mRS 6)Palliated, deceased on day 12. (mRS 6)Case 18Case 19Case 20Case 21Case 22Age/sex61/M67/M66/M64/M52/MEthnicityAsianWhiteBlackWhiteAsianPast medical historyHTN, HLHTN, T2DMNoneGlucose intoleranceAsthmaMedicationsAtorvastatin, amlodipine, clopidogrelAmlodipine, Ramipril, Sitagliptin, MetforminNoneNoneNonePre-stroke mRS00000Frailty score11122COVID symptoms and durationDeveloped cough while inpatient rehab after heart valve intervention3-day history of fever, cough, loss of taste5-day history of fever, mild diarrhoea, nausea, dry cough10-day history of cough and chest pain3-day history of dry cough, fever; 24 h shortness of breathSatO~2~/PaO~2~ (ABG) on admission89% on 3L O~2~78% on RA/PaO~2~ 7.31 kPa on ABG92% on 15L O~2~89% on 15L O~2~/PaO~2~ 7.89 on ABG60% on RAChest X-ray/CT at presentationWidespread bilateral air space infiltrates with pulmonary oedemaBilateral lower zone air space opacities. Obscuration of the left hemidiaphragm is indicative of left lower lobe consolidationExtensive parenchymal lung disease essentially involving the entirety of both lungs, with a ground-glass and consolidative patternScattered bilateral air space opacityBilateral lower lobe and peripheral predominant multiple opacitiesCOVID treatmentIntubation, LMWHIntubation, antibiotics, prophylactic LWMHIntubation, steroid, antibiotics, LMWHIntubation, steroid, LMWHIntubation, steroid, LMWHSigns and symptoms of strokePatient did not wake up after sedation weanLeft arm no movementReduced GCS, no limb movementNew fixed dilated pupilsSlow wake up after sedation weanStroke onset to presentationUnknownUnknownUnknownUnknownUnknownVascular territoryBilateral MCABilateral MCARight MCA and post circulationRight MCA−Imaging for diagnosisCTMRICTCTMRIImaging findingsBilateral MCA and thalami hypodensity, mostly acute ischemiaMRI: Multiple acute border zone infarcts bilaterally in the anterior circulation and some in the posterior circulation occurring in the context of multifocal proximal intracranial arterial stenosesRight MCA and brainstem ischemiaMultifocal intraparenchymal cerebral haemorrhages and subarachnoid haemorrhage (haemorrhagic infarction), diffuse brain oedemaDiffuse haziness throughout the deep cerebral and cerebellar white matter, may be caused by the metabolic/physiological disturbance caused by critical illnessEvidence of PENo PE on CT-PANo CT-PANo PE on CTPASmall PE on CT-PADistal small PE on CT-PAWhite-cell count- × 10^9^/L19.8↑14.9↑38.4↑18.8↑11.4↑Lymphocytes count- × 10^9^/L0.4↓0.2↓0.3↓0.5↓0.4↓Platelet count- × 10^9^/L129635↑473↑577↑272High-sensitivity C reactive protein-mg/L364↑↑335↑345↑388↑338↑Prothrombin time/INR1.2↑1.3↑1.3↑1.01.3↑activated partial thromboplastin time ratio2.8↑1.112.5↑2.52↑1.64↑Fibrinogen-mg/dl6.3↑13.7↑8.3↑8.7↑7.9↑D-Dimer-ng/ml\> 6000↑↑4097↑\> 6000↑↑\> 6000↑↑1124↑Ferritin-µg/ml927↑1651↑1049↑4459↑1233↑Albumin-g/L15↓15↓14↓14↓15↓Clinical outcomeDeceased on day 28 (mRS 6)Renal failure, deceased on day 11. (mRS 6)Renal failure, deceased on day 4. (mRS 6)Renal failure, deceased on day 17 (mRS 6)Improved, continue ward rehabilitation (mRS 4)*ABG* arterial blood gas, *AF* atrial fibrillation, *CT* computed tomography, *CTPA* CT pulmonary angiogram, *F* female, *HL* hyperlipidaemia, *HTN* hypertension, *ICU* intensive care unit, *INR* international normalized ratio, *LMWH* low molecular weight heparin, *M* male, *MCA* middle cerebral artery, *MRI* magnetic resonance imaging, *mRS* modified Rankin scale, *NC* nasal cannula, *NIHSS* national institute of health stroke scale, *PaO*~*2*~ partial pressure of oxygen, *PCA* posterior cerebral artery, *PE* pulmonary embolus, *RA* room air, *SatO*~*2*~ oxygen saturation, *T2DM* type II diabetes mellitusThe reference ranges are as follows: activated partial thromboplastin time ratio, albumin, 35--50 g/L; 0.85--1.15; D-dimer, 21--300 ng/ml; ferritin, 30--400 µg/ml; fibrinogen, 1.6--4.8 mg/dl; high-sensitivity C-reactive protein, 0--5 mg/L; lymphocyte count, 1.1--4.0 × 10^9^/L, platelet count, 150--450 × 10^9^/L, prothrombin time/INR ratio, 0.8--1.1; white-cell count, 4--11 × 10^9^/L.

Twelve community acquired COVID-19 patients (Cases 6--17) developed stroke within 72 h of showing COVID-19 symptoms. Ten patients presented with fever, six had also cough, three patients had severe hypoxia on admission (87% on 15 L O~2~ in case 7, 70% on 15 L O~2~ in case 16 and 89% on 15 L O~2~ in case 17). These three patients are care home residents, have high pre-admission mRS and frailty score. Cases 6--8, 10--12, 14--15 and 17 had confirmed large vessels stroke. Two cases (13 and 16) were clinically unstable on admission and diagnosed without brain imaging. Cases 6, 9--14 and 17 of ischaemic stroke patients with known symptom onset presented late (\> 4.5 hr). Case nine had intraventricular haemorrhage due to a suspected arterio-venous malformation (AVM). We noted that the majority of the patients who died had high CRP. Patients who had hypoxia and abnormal chest X-ray at presentation except case 14, did not survive. Difficult to ascertain whether patients of community acquired COVID-19 developed stroke as a different disease process or as a result of COVID-19. The patients' pre-morbid status and clinical findings in this group suggest that perhaps these patients developed stroke as an additional disease to their COVID-19 infection.

We report five cases (18--22) where patients had severe COVID-19 disease and developed (apart from case 22 which is a stroke mimic) multiorgan failure and large vessel stroke. These patients are middle age males with pre-admission mRS of zero and very low frailty score. Presenting symptoms were typically of COVID-19. All shared chest radiographs abnormalities. They also had abnormally low oxygen saturation on admission and all needed intubation, ventilation and intensive care management. Apart from the stroke mimic case, all had high D-Dimer, ferritin and CRP. These cases share pro-thrombotic characteristics with most of the cases of Morassi et al. \[[@CR2]\]. They all received full anticoagulation with low molecular weight heparin. Four out of these patients had CT pulmonary angiogram with no major pulmonary emboli (PE), suggesting PE may not be the major cause of their death. Further studies into this subpopulation are needed.

We included all COVID-19 stroke patients diagnosed within the period 23rd March and 1st May 2020. However, not all COVID-19 patients had brain scans and, therefore, the number of cases who were diagnosed with stroke due to severe COVID-19 disease may be underestimated. We present the management and outcome of a full spectrum of COVID-19-stroke patients in a tertiary centre. A pro-thrombotic state was found in severe COVID-19 patients, who did not do well, and stroke may be a late complication in these patients. Classifying COVID-19-stroke patients the way we did may help understand the disease and guide management.
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